We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Signaling through JAK1 and/or JAK2 is common among tumor and nontumor cells within
peripheral T-cell lymphoma (PTCL). No oral therapies are approved for PTCL, and better …

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells.
Most patients with T-PLL present with lymphocytosis, anemia, thrombocytopenia, and …

A chromosome 14 inversion was found in a patient who developed bone marrow aplasia
following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene …

T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell
leukemia. Recent studies detected genomic aberrations affecting JAK and STAT genes in T …

Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The
rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive …

T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm usually associated with
rearrangements of TCL1 or MTCP1 [1]. Cases of T-cell leukemia showing overlapping …

Simple Summary T-cell leukemia/lymphoma 1A (TCL1A) is a proto-oncogene that is mainly
expressed in embryonic and fetal tissues, as well as in some lymphatic cells. It is frequently …

Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as
cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity …

Purpose of Review T cell prolymphocytic leukemia (T-PLL) is a rare mature T cell tumor.
Available treatment options in this aggressive disease are largely inefficient and patient …